Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.290
+0.010 (0.78%)
Aug 6, 2026, 10:45 AM EDT - Market open
Ocugen Revenue
Ocugen had revenue of $1.49M in the quarter ending June 30, 2026, with 8.38% growth. This brings the company's revenue in the last twelve months to $4.58M, down -3.66% year-over-year. In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth.
Revenue (ttm)
$4.58M
Revenue Growth
-3.66%
P/S Ratio
94.59
Revenue / Employee
$39,491
Employees
116
Market Cap
436.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.41M | 358.00K | 8.83% |
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 99.61M |
| Prothena Corporation | 57.94M |
| Editas Medicine | 47.01M |
| vTv Therapeutics | 36.84M |
| Scribe Therapeutics | 36.28M |
| Prelude Therapeutics | 16.72M |
| SL Science Holding | 3.27M |
OCGN News
- 2 hours ago - Ocugen Earnings Call Transcript: Q2 2026 - Transcripts
- 2 hours ago - Ocugen Earnings release: Q2 2026 - Filings
- 2 hours ago - Ocugen reports Q2 EPS (7c), consensus (5c) - TheFly
- 3 hours ago - Ocugen Provides Business Update with Second Quarter 2026 Financial Results - GlobeNewsWire
- 6 days ago - Ocugen to Participate in Upcoming August Investor Conferences - GlobeNewsWire
- 7 days ago - Ocugen Proxy statement: Proxy filing - Filings
- 7 days ago - Ocugen Proxy statement: Proxy filing - Filings
- 8 days ago - Ocugen granted RMAT designation for OCU410 - TheFly